MX360662B - Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas. - Google Patents

Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas.

Info

Publication number
MX360662B
MX360662B MX2017002495A MX2017002495A MX360662B MX 360662 B MX360662 B MX 360662B MX 2017002495 A MX2017002495 A MX 2017002495A MX 2017002495 A MX2017002495 A MX 2017002495A MX 360662 B MX360662 B MX 360662B
Authority
MX
Mexico
Prior art keywords
doxylamine
pyridoxine
component
active ingredient
metabolites
Prior art date
Application number
MX2017002495A
Other languages
English (en)
Other versions
MX2017002495A (es
Inventor
Vranderick Manon
Gallo Michele
Gervais Éric
Luc ST-ONGE Jean-
Original Assignee
Duchesnay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duchesnay Inc filed Critical Duchesnay Inc
Publication of MX2017002495A publication Critical patent/MX2017002495A/es
Publication of MX360662B publication Critical patent/MX360662B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una forma de dosificación oral sólida que comprende un núcleo que comprende un componente de doxilamina y un componente de piridoxina revestido con un revestimiento entérico. La forma de dosificación oral sólida comprende además dos revestimientos que contienen ingrediente activo que rodean el revestimiento entérico, los revestimientos que contienen ingrediente activo se separan uno del otro por un revestimiento intermedio, y uno de los dos revestimientos contiene ingrediente activo que comprende un componente de doxilamina y está libre de un componente de piridoxina, y el otro de los dos revestimientos contiene ingrediente activo que comprende un componente de piridoxina y está libre de componente de doxilamina. También se describen los usos de la forma de dosificación oral sólida para el alivio de los síntomas de náuseas y vómito, por ejemplo en el caso de náuseas y vómito del embarazo (NVP).
MX2017002495A 2014-08-29 2014-08-29 Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas. MX360662B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2014/050828 WO2016029290A1 (en) 2014-08-29 2014-08-29 Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Publications (2)

Publication Number Publication Date
MX2017002495A MX2017002495A (es) 2017-09-13
MX360662B true MX360662B (es) 2018-11-13

Family

ID=55398524

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002495A MX360662B (es) 2014-08-29 2014-08-29 Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas.

Country Status (25)

Country Link
EP (1) EP3185856B1 (es)
JP (1) JP6272561B2 (es)
KR (1) KR101831570B1 (es)
CN (1) CN106794148B (es)
AR (1) AR101728A1 (es)
AU (1) AU2014405049B2 (es)
CA (1) CA2920247C (es)
CY (1) CY1120788T1 (es)
DK (1) DK3185856T3 (es)
EA (1) EA032671B1 (es)
ES (1) ES2674996T3 (es)
FR (1) FR24C1000I1 (es)
HU (1) HUE038969T2 (es)
IL (1) IL250541B (es)
MX (1) MX360662B (es)
MY (1) MY196073A (es)
PH (1) PH12017500282B1 (es)
PL (1) PL3185856T3 (es)
PT (1) PT3185856T (es)
SA (1) SA517380942B1 (es)
SG (1) SG11201701448XA (es)
TR (1) TR201809565T4 (es)
UA (1) UA118711C2 (es)
WO (1) WO2016029290A1 (es)
ZA (1) ZA201701063B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053082T2 (hu) 2018-09-27 2021-06-28 Inibsa Ginecologia S A Eljárás doxilamin-szukcinát- és piridoxin-hidroklorid-tartalmú, módosított hatóanyag-leadású, több kis egységet tartalmazó, orális adagolási forma elõállítására
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
CA2350195C (en) * 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
TWI292138B (en) * 2004-03-11 2008-01-01 Mstar Semiconductor Inc Device for adaptively adjusting video's luminance and related method
SI1814527T1 (sl) * 2004-11-05 2014-03-31 Boehringer Ingelheim International Gmbh Dvoslojna tableta, ki obsega telmisartan in amlodipin
RU2011142081A (ru) * 2009-03-20 2013-04-27 Новартис Аг Галеновые фиксированные комбинации валсартана и алискирена
EP2500016A1 (en) * 2011-03-18 2012-09-19 Laboratorios Del. Dr. Esteve, S.A. Doxylamine resinate complex
CA2761212A1 (en) * 2011-12-07 2013-06-07 Pharmascience Inc. Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing
WO2013123569A1 (en) * 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
CN104136004B (zh) * 2012-02-22 2018-03-06 达切斯内公司 多西拉敏和吡哆醇和/或其代谢物或盐的制剂

Also Published As

Publication number Publication date
BR112017004190A2 (pt) 2017-12-12
UA118711C2 (uk) 2019-02-25
IL250541A0 (en) 2017-03-30
AR101728A1 (es) 2017-01-11
CN106794148B (zh) 2018-12-21
SG11201701448XA (en) 2017-03-30
CN106794148A (zh) 2017-05-31
AU2014405049A1 (en) 2017-04-06
EP3185856A1 (en) 2017-07-05
DK3185856T3 (en) 2018-07-30
TR201809565T4 (tr) 2018-07-23
AU2014405049B2 (en) 2017-04-20
WO2016029290A1 (en) 2016-03-03
EP3185856B1 (en) 2018-05-23
NZ729042A (en) 2021-01-29
KR20170046163A (ko) 2017-04-28
CA2920247A1 (en) 2016-02-29
PH12017500282A1 (en) 2017-06-28
EA032671B1 (ru) 2019-06-28
CA2920247C (en) 2017-01-03
SA517380942B1 (ar) 2021-05-16
JP2017525731A (ja) 2017-09-07
PT3185856T (pt) 2018-10-09
KR101831570B1 (ko) 2018-02-22
ZA201701063B (en) 2019-11-27
JP6272561B2 (ja) 2018-01-31
EA201790477A1 (ru) 2017-07-31
EP3185856A4 (en) 2017-09-13
MX2017002495A (es) 2017-09-13
MY196073A (en) 2023-03-13
PH12017500282B1 (en) 2017-06-28
HUE038969T2 (hu) 2018-12-28
FR24C1000I1 (fr) 2024-02-23
PL3185856T3 (pl) 2018-09-28
CY1120788T1 (el) 2020-05-29
IL250541B (en) 2018-12-31
ES2674996T3 (es) 2018-07-05

Similar Documents

Publication Publication Date Title
EP3270992A4 (en) Vaporizer for vaporizing an active ingredient
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
EP3644974A4 (en) VAPORIZATION DEVICES AND METHODS FOR RELEASING A COMPOUND USING THEM
WO2016176473A8 (en) Apelin receptor agonists and methods of use thereof
PH12016500626A1 (en) Film coated tablet containing choline alfoscerate and process for preparing the same
MX355912B (es) Formulación de doxilamina y piridoxina y/o sus metabolitos o sales.
WO2014204881A8 (en) Delayed release cysteamine bead formulation
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
AU2018300075A1 (en) Dual release dosage form capsule and methods, devices and systems for making same
MY189306A (en) Tablet
SA517380942B1 (ar) صيغة إطلاق متعددة النماذج للدوكسيلامين والبيريدوكسين و/أو نواتج أيض أو أملاح منها
TW201613584A (en) Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
WO2015095659A3 (en) Indirubin solid dispersion composition
MX2017006168A (es) Composiciones.
EP3459933A3 (en) Solid forms of a pharmaceutically active compound
EP3481379A4 (en) ORAL GALENIC FORM CONTAINING A QUICK RELEASE EXTERIOR COATING
EP3127555B8 (en) Coating agent for solid preparation, and film and coated solid preparation formed therewith
NZ628867A (en) Pharmaceutical formulation containing flupirtine
MX2016008225A (es) Composiciones para cuidado oral y metodos.
TH1701000973A (th) สูตรผสมที่มีการปลดปล่อยหลายแบบของดอกซีลามีนและไพริดอกซีนและ/หรือเมแทบอไลต์หรือเกลือของสิ่งนั้น
UY36283A (es) Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas
UA89127U (uk) Спосіб лікування антифосфоліпідного синдрому
MX2018002449A (es) Formulaciones de liberacion retardada, metodos de fabricacion y uso de las mismas.
EA201891885A1 (ru) Содержащая прегабалин высоконабухаемая трехслойная таблетка с замедленным высвобождением для перорального приема
UA102073U (uk) Фармацевтичний препарат на основі сератіопептидази у формі таблеток

Legal Events

Date Code Title Description
FG Grant or registration